Records containing: Secondary Progressive Multiple Sclerosis
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-03The Impact of Diet Quality and Calorie Restriction on Physical Function and Patient Reported Outcomes in Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2026-03-20A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-active Secondary Progressive Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2026-02-13An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2026-01-06A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI)
-
CLINICAL_TRIALS study record update · 2025-10-15A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-09-11Retrospective, Multicenter, Non-interventional (Observational) Study With the Aim to Describe the Impact of Siponimod Treatment in a Real-world SPMS Population in Russia
-
CLINICAL_TRIALS study record update · 2025-09-04Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis: A Phase 1b Randomised, Double-blind, Placebo-controlled Trial.
-
CLINICAL_TRIALS study record update · 2025-07-28Danish Non-inferiority Study of Ocrelizumab and Rituximab in MS (DanNORMS): A Randomized Study Comparing the Efficacy of Ocrelizumab and Rituximab in Active Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2025-07-25Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme
-
CLINICAL_TRIALS study record update · 2025-07-22A Double-blind, Placebo Controlled Trial of Metformin Treatment in Progressive Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2025-07-01A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis: Impact on Vascular Perfusion and Oxidative Damage
-
CLINICAL_TRIALS study record update · 2025-06-02Cladribine Tablets as an Exit Therapy Strategy: Alternative to Continuing Treatment and Plain Treatment Discontinuation in Ageing Stable RMS Patients
-
CLINICAL_TRIALS study record update · 2025-02-11Treatment of Progressive Forms of Multiple Sclerosis With Pulsed ACTH (Acthar Gel)
-
CLINICAL_TRIALS study record update · 2024-09-19Observational Retrospective Study to Assess the Use of Siponimod (Mayzent) on Patients With Secondary Progressive Multiple Sclerosis in Clinical Practice in Spain - RESYZE Study
-
CLINICAL_TRIALS study record update · 2024-07-29Retrospective EMR Study to Assess Changes in Immunoglobulins in Patients With Relapsing Forms of Multiple Sclerosis Treated With Anti-CD20 Monoclonal Antibodies
-
CLINICAL_TRIALS study record update · 2024-05-17An Open-label Multicenter Study to Assess Response to SARS-CoV-2 modRNA Vaccines in Participants With Secondary Progressive Multiple Sclerosis Treated With Mayzent (Siponimod)
-
CLINICAL_TRIALS study record update · 2024-05-02A Real-World, Retrospective, Multicenter Study to Assess the Effectiveness and Safety of Mayzent® (Siponimod) in Chinese Patients With Relapsing Forms of Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2024-02-23A Phase 1/2, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study With an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2023-09-26Novel Imaging Markers of Innate Immune Activation in Secondary Progressive Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2023-04-24Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo
-
CLINICAL_TRIALS study record update · 2022-03-03A Phase 1b, Double-Blind, Randomized, Placebo Controlled, Multiple Ascending Dose Study of the Safety, Tolerability and Immune Effects of the Intranasal Anti-CD3 Monoclonal Antibody Foralumab in Primary and Secondary Progressive MS
-
CLINICAL_TRIALS study record update · 2022-01-18Measuring Active Microglia in Progressive Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2021-07-09A Phase IV Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2021-03-08Patient Research Cohort: Rapidly Evolving Multiple Sclerosis Opening the Window of Therapeutic Opportunity
-
CLINICAL_TRIALS study record update · 2020-11-09Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis (AMS04)